7-30964097-T-G
Variant summary
Our verdict is Uncertain significance. The variant received 0 ACMG points: 0P and 0B.
The NM_000823.4(GHRHR):c.29T>G(p.Val10Gly) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000199 in 1,550,080 control chromosomes in the GnomAD database, with no homozygous occurrence. 16/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V10I) has been classified as Likely benign.
Frequency
Consequence
NM_000823.4 missense
Scores
Clinical Significance
Conservation
Publications
- isolated growth hormone deficiency type IBInheritance: AR Classification: DEFINITIVE, SUPPORTIVE Submitted by: Laboratory for Molecular Medicine, Orphanet
- isolated growth hormone deficiency, type 4Inheritance: AR Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GHRHR | NM_000823.4 | c.29T>G | p.Val10Gly | missense_variant | Exon 1 of 13 | ENST00000326139.7 | NP_000814.2 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000250 AC: 38AN: 152184Hom.: 0 Cov.: 33 show subpopulations
GnomAD2 exomes AF: 0.000194 AC: 30AN: 154880 AF XY: 0.000184 show subpopulations
GnomAD4 exome AF: 0.000193 AC: 270AN: 1397896Hom.: 0 Cov.: 32 AF XY: 0.000177 AC XY: 122AN XY: 689522 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.000250 AC: 38AN: 152184Hom.: 0 Cov.: 33 AF XY: 0.000202 AC XY: 15AN XY: 74346 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not provided Uncertain:5
This sequence change replaces valine, which is neutral and non-polar, with glycine, which is neutral and non-polar, at codon 10 of the GHRHR protein (p.Val10Gly). This variant is present in population databases (rs139599160, gnomAD 0.04%). This missense change has been observed in individual(s) with clinical features of growth hormone deficiency sufficient (PMID: 19622623). ClinVar contains an entry for this variant (Variation ID: 360027). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). Experimental studies have shown that this missense change affects GHRHR function (PMID: 19622623). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
- -
- -
Observed as a heterozygous variant in patients with short stature in published literature, although a second GHRHR variant was not reported in all cases (PMID: 19622623, 38087044); Published functional studies suggest a damaging effect with disrupted signal peptide cleavage and receptor localization (PMID: 19622623); In silico analysis indicates that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 38087044, 19622623, LessiM2001[CaseReport]) -
- -
not specified Uncertain:1
Variant summary: GHRHR c.29T>G (p.Val10Gly) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00019 in 154880 control chromosomes (gnomAD). c.29T>G has been reported in the literature in the heterozygous state in individuals affected with Isolated growth hormone deficiency, as well as in unaffected individuals (Godi_2009). This report does not provide unequivocal conclusions about association of the variant with Isolated growth hormone deficiency, type 4. At least one publication reports experimental evidence evaluating an impact on protein function, finding that it disrupts cleavage of the signal peptide and localization to the cell surface (Godi_2009). The following publication has been ascertained in the context of this evaluation (PMID: 19622623). Two submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. Both submitters classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at